India’s pharmaceutical retailing is a large and, on paper, thriving market. Estimated at $30B+ today, it is growing at roughly 10%+ a year. Currently, most of that spend moves through a network of nearly 800,000-900,000 retail pharmacies you can physically walk into. A vast majority of which are small, independently run, and built to serve whoever happens to live within a few streets of the counter.

A market this size and this widely distributed should mean abundance. Whatever medicine is needed should be nearby, in stock, and ready to hand over. In practice, most people who have gone looking for a specific medicine on short notice know the opposite experience. In most cases, the nearest pharmacy doesn't have medicines for a whole patient prescription, and what should take five minutes of a patient’s time stretches into an evening. For someone standing at the counter, the scale of the retail pharmacy market rarely translates into the medicine actually being there.

Much of this is structural, and it comes down to how Indian pharma is prescribed. India is overwhelmingly a branded-generics market. Brand names, not molecule names, dominate over 80% of medical prescriptions, which means a single molecule can carry 50 to 100 competing brands. Layered on this is the fact that every micro-market ends up with its own demand pattern, driven by which brands the local doctors prescribe. A typical neighborhood pharmacy, built for a roughly one-kilometer catchment, is unable to justify the inventory cost of stocking for that complexity, and carries around 5,000 of the market’s 100,000+ SKUs. As a result, prescription fill rates for these pharmacies land at 50-60%, and it is common for a single prescription to send a patient to two or three different pharmacies before it’s complete.

The first generation of e-pharmacies solved this partially through depth, but not through speed. Centralized warehousing gets their fill rates closer to 95%, but delivery still takes one to three days. The economics in this format also only work on higher order values. That combination serves a narrow slice of demand in planned, chronic-care orders, while leaving out everything urgent, small-basket of chronic care, or needed outside a delivery window. It is a structural reason online penetration in Indian pharmacy retail has stayed at around 3%.

A newer set of broad quick-commerce platforms has also entered the category, but their SKU depth remains shallow.

What’s missing in this space is a new-age offline pharmacy built on quick-commerce rails. One with the depth of an e-pharmacy warehouse and the immediacy of quick-commerce. Plazza is building exactly that.

The Plazza Model

Founded by Aman Priyadarshi in 2024, Plazza is a pharmacy-first quick-commerce platform delivering medicines within 15-30 minutes out of Bengaluru, with prescription fill rates above 95%. Their two stores, each with a 500-600 sq. ft. footprint of a standard pharmacy, form the backbone of the model. Here’s how they look on the inside:

• Built for inventory, not just retail. A Plazza store stocks 40,000+ SKUs against the 5,000 a conventional pharmacy of the same size can hold. They achieve this by giving 90% of floor space to storage rather than walk-in display.
• A wider catchment to justify a deeper shelf. Extending delivery to a 3-4 km radius, versus the 1 km a walk-in store realistically serves, aggregates enough demand to make it economical to stock rare, low-frequency medicines.
• Replenishment that learns store by store. An algorithmic engine starts new SKUs at a single unit, reorders automatically after the first sale, and continuously adjusts each store’s assortment to match what its own neighborhood is prescribing. This addresses the variance seen in prescription patterns in micro-markets. For context, the overlap between the two stores’ top-selling SKUs is only 50%, despite comparable disease burden in both micro-markets.
• A real pharmacy counter, not just a warehouse. Keeping stores open to walk-ins accounts for a small share of overall volume. This in turn is an important mechanism to build the trust that gets a first-time customer to order again.

In conversations with Plazza's users, availability and delivery speed came up as the near-universal reason for switching and staying, even though most already had two or three other pharmacy apps on their phones. Plazza also received satisfaction scores of 9 out of 10, high marks for a category where most of the customer relationship happens through an app and a rider.

Many other users arrived by word of mouth rather than an ad. One mother started ordering after her daughter spotted the Bellandur store while picking up medicine for a newborn, and now uses Plazza for her own diabetes medication too. For another patient managing a chronic clotting condition, who had been juggling three different platforms, what kept them on Plazza was a combination of speed, proactive stock alerts, and a teleconsultation option that flagged what they needed before they had to ask.

Different as these paths were, they point to the same dynamic the company is betting on. The fact that trust built during an urgent, one-off order is what eventually pulls a household's routine medicine cabinet onto the platform too.

The Founder Behind the Scenes

Aman built his instincts for operating at the kind of granularity this space requires during his time at Zomato, where he worked on some of the company’s highest-stakes projects. This created the grounding Plazza needed to operate.

His precision in thinking shows up in how the Plazza model is built and in the trade-offs behind each design choice.

Aman has also been deliberate about the team he's building around himself. He has structured leadership hiring around functional verticals and is recruiting operators who have solved versions of these problems before, rather than generalists. Plazza has also built real organic pull across its Bangalore micro-markets in under two years. That’s brand recognition built on word of mouth rather than paid acquisition, while keeping its burn low relative to other vertical quick-commerce businesses at a similar stage.

The Way Ahead

Plazza is built for the segment of pharmacy demand India’s existing infrastructure has never served well. For patients with prescriptions that are urgent, small-basket, and needed right away.

Their model of extending catchment and learning demand at the micro-market level should, in principle, compound with density. The more stores in a city, the better each one gets at knowing what to stock. The early trajectory supports this. Their GMV grew roughly 27-fold between June 2025 and March 2026, and repeat customers now order at an AOV about 30% higher than new customers. A strong signal of the wallet-capture dynamic the model is built around.

We're excited to back Aman and the Plazza team as they build a pharmacy network India can finally trust to meet their entire medical needs. One where availability is the baseline, not the exception, and where a market this large finally delivers on the abundance it always promised.

If you are building in healthcare or healthtech, we would love to hear from you. Reach out to vishap@elevationcapital.com or chirag@elevationcapital.com.

Learn more about our healthcare thesis, team, and portfolio at elevationcapital.com/healthcare